INTRODUCTION
Cystic fi brosis is the most common lethal autosomal recessive hereditary disorder in Caucasians. 1 The prognosis of the disease is substantially dependent on the chronic respiratory infection and infl ammation, a hallmark of CF. 2 Antibiotic therapy aims at eradicating Pseudomonas aeruginosa, the major bacterial pathogen in CF, after early lung infection, and improved regimens to treat chronic P. aeruginosa infection have played a major role in increasing median survival of CF patients to 40 years during the last decades. 3 However, during the last 5 years, reported survival rates appear to have reached a plateau 4 and one of the reasons could be the emergence of new highly-resistant non-pseudomonas strains characteristic for CF such as Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia species 5 . In a recently published study for respiratory bacteriology in CF patients authors found that the average annual percent change in overall prevalence and incidence signifi cantly decreased for P. aeruginosa and B. cepacia complex; almost did not changed for A. xylosoxidans while in contrast signifi cantly increased for S maltophilia. 6 
CASE REPORT
We present a case of cystic fi brosis in a 16- 9 A combination of doxycycline and aerosolized colistin was successfully used to treat persistent S. maltophilia ventilator-associated pneumonia when high-dose TMP-SMX therapy was ineffective. 10 Regarding colistin, the breakpoints established 
DISCUSSION
Chronic infection is the main determinant of morbidity and mortality in individuals with cystic fi brosis (CF). 4 The bacteria most commonly believed to be pathogenic in CF include P. aeruginosa, S. aureus, H. infl uenzae, S. maltophilia, A. xylosoxidans, and B. cepacia complex. It is suggested that S. maltophilia is a low pathogenic species as it has limited growth in sputum from chronically infected CF patients 11 which may be due to low O 2 availability in the endobronchial mucus in CF patients 12 caused by the intense O 2 consumption by activated PMNs 13 .
In the 1960s and 1970s, P. aeruginosa was initially not realized as a pathogen for CF patients and there were still reports until 1990 questioning its signifi cance, while nowadays a huge part of the therapy in CF is targeted in eradicating and preventing this bacterium. The similarities in biofi lm formation of S. maltophilia poses same concerns for its signifi cance in CF. 5 Since 2010 its presence has been also part of the monitored variables in CF patients for the registry. Data from several CF centres worldwide indicate that the prevalence of S. maltophilia has increased in recent years. 14 Many retrospective studies show confl icting data about whether S. maltophilia is associated with lung function decline, but in one of the recent papers by Pompillo, its role in lung pathology is discussed. 15 Chronic S. maltophilia infection is an independent risk factor for pulmonary exacerbation. 16, 17 S. maltophilia exhibits intrinsic resistance to broad-spectrum antibiotics, including beta-lactams and aminoglycosides; and thus the treatment options are limited. 18, 19 Recommended antibiotics for therapy against S. maltophilia infections in patients with CF are minocycline, doxycycline, trimethoprim/ sulfamethoxazole, colistin, and ticarcillin/clavulanic acid. 16 Regarding antimicrobial susceptibility, only a few studies have performed susceptibility testing for S. maltophilia on samples from CF patients. 20 Goncalves-Vidigal et al. in a recent study demonstrated that tigecycline (not available in Bulgaria) and trimethoprim/sulfamethoxazole exhibit 100% activity against S. maltophilia, while colistin, ceftazidime, and ticarcillin/clavulanic acid exhibited low activity against this pathogen. 16 Their results are not consistent with the higher resistance rates for trimethoprim/sulfamethoxazole in USA CF patients 21 but are in concordance with a Turkish study from 2007 confi rming trimethoprim/sulfamethoxazole as the most active antibiotic (all isolates were susceptible) and levofl oxacin getting the second place with susceptible 82% of isolates 22 .
These studies claim that colistin demonstrates limited activity against S. maltophilia isolates from CF patients. However, CLSI guidelines have not yet established specifi c breakpoints as interpretive criteria for colistin (administered through inhalation and not parenterally) against S. maltophilia. 8 The case is interesting for us due to microorganism susceptibility only to levofl oxacin, an antibiotic used very often even for minor infections, and resistant to all other available antibiotics on the market (including trimethoprim/sulfamethoxazole and colistin). In Bulgaria, to the best of our knowledge so far, all tested S. maltophilia strains were 100% susceptible to colistin [unpublished data]. This fact could be due to the very high cost of the antibiotic that should be paid by the National Health Insurance fund since April 2016 23 , and up until now the patients have had to pay for it themselves, and not all of them could afford it. Also, colistin was re-introduced to our market just last year and we are using it as antibiotic of last resort in all multidrug-resistant gram-negative infections in CF patients. 24 Another point of concern for our patient is also the high prevalence of self-treatment with antibiotics in Bulgaria, found as acceptable from 73% of the studied representative part of Bulgarian population. 25 Research conducted in southern Europe indicate that between 75% and 94% of the total use of antibiotics occurs in outpatient care. 26 At present in Bulgaria antibiotics such as levofl oxacin (our only option for the patient) and trimethoprim/sulfamethoxazole counted as "cheap and not so potent" antibiotics are widely accepted and prescribed even when not needed. 27 Additionally, although in 2009 in Bulgaria a strict antibiotic policy was introduced for obligatory prescription for antibiotics, recent journalistic investigation showed that buying antibiotics without prescription Folia Medica I 2016 I Vol. 58 I No. 2 I Article 9 in pharmacies is still easily done. 28 To the best of our knowledge, this is the fi rst CF patient with isolated S. maltophila resistant to colistin in Bulgaria. We will continue to monitor the patient closely in future to re-evaluate the therapy according the isolated microorganism susceptibility.
